Please login to the form below

Not currently logged in
Email:
Password:

Roche and Covagen collaborate

Roche has entered into a collaboration agreement with Covagen, a Swiss biotechnology company

Roche has entered into a collaboration agreement with Covagen, a Swiss biotechnology company that is developing next generation protein drugs for the treatment of diseases using Fynomer technology at the Institute of Pharmaceutical Sciences at ETH Zurich. 

Covagen's innovative platform comprises a novel single domain protein scaffold, which - in analogy to antibodies - can be engineered to yield high affinity binding proteins (Fynomers) that can be used for therapeutic applications. Covagen filed patent applications to protect its drug development platform, allowing it to become active in a new field of intellectual property, which is a significant advantage compared with the antibody field that has been widely claimed already.

Under the terms of the agreement with Roche, Covagen will use its protein engineering technology to isolate Fynomers binding to undisclosed targets provided by Roche. Fynomers delivered by Covagen will be further tested and evaluated by Roche to discover potential new treatments for patients with unmet medical needs. 

Dr Dragan Grabulovski, CSO and co-founder of Covagen commented: "This collaboration with Roche represents a further step to establish Covagen's Fynomers as new binding proteins for a variety of applications in drug discovery."

The financial terms of the collaboration agreement have not been disclosed.

22nd June 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GEM Marketing Ltd

GEM, a small but perfectly formed integrated marketing agency servicing the pharmaceutical industry....

Latest intelligence

Australian Flu and the dilemma of naming diseases
...
Wearables and Healthcare
What place do wearables have in affecting actual patient health outcomes and can they contribute to the NHS’s sustainability agenda? Or are they just the latest fad?...
What does a future-proof rep look like?
Businesses can no longer afford to push ahead with the traditional Key Account Management model....

Infographics